{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:29:57Z","timestamp":1792898997767,"version":"4.5.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.clml.2023.09.008","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T21:40:03Z","timestamp":1695937203000},"page":"122-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3173-5918","authenticated-orcid":false,"given":"Tammy A.","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djibril","family":"Liassou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marn\u00e9","family":"Garretson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7117-6124","authenticated-orcid":false,"given":"Taavy A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankar","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"McBride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3190-5227","authenticated-orcid":false,"given":"Irene S.","family":"DeGutis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Kish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Feinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3422-1309","authenticated-orcid":false,"given":"Aaron T.","family":"Gerds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.09.008_bib0001","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.hoc.2020.12.001","article-title":"Overview of myeloproliferative neoplasms: history, pathogenesis, diagnostic criteria, and complications","volume":"35","author":"Tremblay","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2023.09.008_bib0002","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2023.09.008_bib0003","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3109\/10428194.2013.813500","article-title":"Epidemiology of myeloproliferative neoplasms in the United States","volume":"55","author":"Mehta","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.09.008_bib0004","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/MOH.0000000000000218","article-title":"New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms","volume":"23","author":"Passamonti","year":"2016","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.clml.2023.09.008_bib0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.09.008_bib0006","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1080\/10428194.2016.1195501","article-title":"Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence","volume":"57","author":"Harrison","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.09.008_bib0007","doi-asserted-by":"crossref","first-page":"10777","DOI":"10.2147\/CMAR.S212559","article-title":"Beyond ruxolitinib: fedratinib and other emergent treatment options for myelofibrosis","volume":"11","author":"Bewersdorf","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clml.2023.09.008_bib0008","unstructured":"US Food and Drug Administration. INREBIC\u00ae highlights of prescribing information. 2019. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212327s004lbl.pdf. Accessed: April 6, 2023."},{"key":"10.1016\/j.clml.2023.09.008_bib0009","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bjh.17727","article-title":"Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis","volume":"195","author":"Pardanani","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.09.008_bib0010","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.25777","article-title":"Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure","volume":"95","author":"Harrison","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2023.09.008_bib0011","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.leukres.2017.05.012","article-title":"Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials","volume":"59","author":"Gwaltney","year":"2017","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2023.09.008_bib0012","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:59Z","timestamp":1761871379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023021304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2152265023021304"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.09.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}